Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
2.
Acta Derm Venereol ; 90(1): 73-6, 2010.
Article in English | MEDLINE | ID: mdl-20107730

ABSTRACT

Cutaneous adverse effects of imatinib mesylate (Glivec) are common and various types of skin eruptions have been reported. We report here a 57-year-old man who presented with lichen planus-like lesions on his extremities and palmoplantar hyperkeratosis due to the use of imatinib mesylate for chronic myeloid leukaemia. The skin lesions improved after discontinuation of imatinib mesylate but re-administration of the drug at a lower dose provoked a mild recurrence. He could, however, continue to take the drug at the lower dose and his skin lesions were well-controlled by topical corticosteroid treatment. The literature on lichenoid drug eruption due to imatinib mesylate is reviewed.


Subject(s)
Antineoplastic Agents/adverse effects , Drug Eruptions/etiology , Keratoderma, Palmoplantar/chemically induced , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Lichenoid Eruptions/chemically induced , Piperazines/adverse effects , Pyrimidines/adverse effects , Administration, Topical , Adrenal Cortex Hormones/administration & dosage , Aged , Aged, 80 and over , Antineoplastic Agents/administration & dosage , Benzamides , Dermatologic Agents/administration & dosage , Dose-Response Relationship, Drug , Drug Eruptions/drug therapy , Drug Eruptions/pathology , Female , Humans , Imatinib Mesylate , Keratoderma, Palmoplantar/drug therapy , Keratoderma, Palmoplantar/pathology , Lichenoid Eruptions/drug therapy , Lichenoid Eruptions/pathology , Male , Middle Aged , Piperazines/administration & dosage , Pyrimidines/administration & dosage , Recurrence , Skin/pathology , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...